Pharmacokinetics of ertapenem in patients with multidrug-resistant tuberculosis

Sander P. van Rijn1,7, Richard van Altena2,7, Onno W. Akkerman2, Dick van Soolingen3,4, Tridia van der Laan4, Wiel C.M. de Lange2, Jos G.W. Kosterink1,5, Tjip S. van der Werf6 and Jan-Willem C. Alffenaar1

Affiliations: 1University of Groningen, University Medical Center Groningen, Dept of Clinical Pharmacy, Groningen, The Netherlands. 2University of Groningen, University Medical Center Groningen, Tuberculosis Center Beatrixoord, Haren, The Netherlands. 3Radboud University Nijmegen Medical Center, Depts of Pulmonary Diseases and Medical Microbiology, Nijmegen, The Netherlands. 4National Tuberculosis Reference Laboratory, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands. 5University of Groningen, University Medical Center Groningen, Section Pharmacotherapy and Pharmaceutical Care, Dept of Pharmacy, Groningen, The Netherlands. 6University of Groningen, University Medical Center Groningen, Depts of Internal Medicine and Pulmonary Diseases and Tuberculosis, Groningen, The Netherlands. 7Both authors contributed equally.

Correspondence: Jan-Willem C. Alffenaar, University of Groningen, University Medical Center Groningen, Dept of Hospital and Clinical Pharmacy, P.O. Box 30.001, 9700 RB Groningen, The Netherlands. E-mail: j.w.c.alffenaar@umcg.nl

ABSTRACT  Treatment of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) is becoming more challenging because of increased levels of drug resistance against second-line TB drugs. One promising group of antimicrobial drugs is carbapenems. Ertapenem is an attractive carbapenem for the treatment of MDR- and XDR-TB because its relatively long half-life enables once-daily dosing.

A retrospective study was performed for all patients with suspected MDR-TB at the Tuberculosis Center Beatrixoord of the University Medical Center Groningen (Haren, the Netherlands) who received ertapenem as part of their treatment regimen between December 1, 2010 and March 1, 2013. Safety and pharmacokinetics were evaluated.

18 patients were treated with 1000 mg ertapenem for a mean (range) of 77 (5–210) days. Sputum smear and culture were converted in all patients. Drug exposure was evaluated in 12 patients. Drug exposure was evaluated in 12 patients. The mean (range) area under the concentration–time curve up to 24 h was 544.9 (309–1130) h·mg·L\(^{-1}\). The mean (range) maximum observed plasma concentration was 127.5 (73.9–277.9) mg·L\(^{-1}\).

In general, ertapenem treatment was well tolerated during MDR-TB treatment and showed a favourable pharmacokinetic/pharmacodynamic profile in MDR-TB patients. We conclude that ertapenem is a highly promising drug for the treatment of MDR-TB that warrants further investigation.

@ERSpublications
Pharmacokinetic and safety data show ertapenem to be a promising drug for MDR-TB treatment
http://ow.ly/V69DD
Introduction
Treatment of multidrug-resistant (MDR) and extensively drug-resistant tuberculosis (TB) is becoming more challenging because of increased levels of drug resistance against second-line TB drugs. New drugs are being evaluated in clinical trials, but only bedaquiline and delamanid have entered the market to date. Therefore, antimicrobial drugs, which have been developed and labelled for other bacterial infections, may be of potential use in the treatment of MDR-TB.

One promising group of antimicrobial drugs is carbapenems [1, 2]. An early in vitro experiment showed that imipenem and meropenem were active against Mycobacterium tuberculosis [3]. Chambers et al. [4] showed that imipenem has antimycobacterial activity in mice and humans. Imipenem and meropenem are currently listed as group 5 drugs for the treatment of MDR-TB [5]. More recently, clinical experience of carbapenems in MDR-TB patients showed promising results [6, 7].

Carbapenems are poor substrates for β-lactam C (BLaC) due to rapid acylation and slow deacylation. Therefore, unlike β-lactams, they are not rapidly hydrolysed by BLaC and thus maintain their potential activity against M. tuberculosis [8]. The binding of carbapenems to L,D-transpeptidases results in inhibition of the peptidoglycan polymerisation of the cell wall [9]. Combined with a β-lactamase inhibitor, such as clavulanate, activity against M. tuberculosis is higher [10].

Efficacy of carbapenems is correlated with the percentage of time the free plasma drug concentration transcends the minimum inhibitory concentration (MIC) (free>MIC). Maximal bactericidal activity is reached if the free>MIC is >40% of the dosing interval [11, 12]. To reach this target for Gram-positive, Gram-negative and anaerobic bacterial infections, ertapenem is given intravenously at a dose of 1000 mg once daily [13]. Ertapenem has the advantage over other carbapenems of a long half-life of 4 h, enabling once-daily dosing [12], which is attractive for MDR-TB treatment. Another advantage is that ertapenem is not affected by drug-drug interactions as it is neither metabolised by cytochrome P450 nor a substrate for P-glycoprotein [14].

To include ertapenem among the other carbapenems as a group 5 drug for the treatment of MDR-TB, additional pharmacokinetic and safety data are urgently needed [15]. Therefore, the objective of this study was to evaluate pharmacokinetics and safety in patients that received ertapenem as part of their treatment regimen for MDR-TB.

Patients and methods
Patients
All patients suspected of MDR-TB at the Tuberculosis Center Beatrixoord of the University Medical Center Groningen (Haren, the Netherlands) who received ertapenem as part of their treatment regimen between December 1, 2010 and March 1, 2013 were included in this retrospective study. The study was evaluated by the Medical Ethical Review Board of the University Medical Center Groningen (METC 2013-492). The need for written informed consent was waived for the retrospective collection and analysis of anonymous data because it was not required under Dutch law (Medical Research Involving Human Subjects Act (WMO)). For each MDR-TB suspect, the following data were collected: age, sex, weight, height, ethnicity, drug susceptibility pattern, localisation of TB, antiretroviral therapy, sputum conversion, adverse effects (AEs) induced by ertapenem, dose, total exposure to ertapenem and duration of treatment.

Drug susceptibility to ertapenem
Drug susceptibility testing of ertapenem was performed with and without clavulanic acid using the Middlebrook 7H10 agar dilution method at the Dutch National Tuberculosis Reference Laboratory (National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands) [16].

Pharmacokinetics and pharmacodynamics
All patients received ertapenem at a dosage of 1000 mg once daily, given as i.v. infusion in 30 min. In all MDR-TB patients, routine plasma concentrations were collected at steady state to assess drug exposure and thus enable individualised dosing. For plasma sampling, a peripheral i.v. catheter was inserted. Patency of the peripheral catheter was maintained by a saline drip. Before a blood sample was taken, the drip was stopped and the first 4 mL of blood were discarded. The samples were collected before administration and at 1, 2, 3, 4, 5, 6, 8 and 12 h post dosage and stored at −80°C until analysis. Plasma concentrations were assessed and validated using a validated liquid chromatography-tandem mass spectrometry method in the Laboratory of Clinical Toxicology and Drugs Analysis of the Dept of Clinical Pharmacy and Pharmacology at the University Medical Center Groningen (Groningen, the Netherlands) [17]. Population pharmacokinetic parameters were calculated using the KinPop module. Both KinFIT and KinPOP were part of the software package MWPharm 3.82 (Mediware Information Systems B.V., Eindhoven, the Netherlands). The free>MIC was calculated as this has been proposed to be the best pharmacokinetic/pharmacodynamic parameter to predict in vivo efficacy of carbapenems [10]. The free drug concentration...
was assumed to be 5% [12, 18]. European Committee on Antimicrobial Susceptibility Testing (EUCAST) MIC values for ertapenem (non-species related) of 0.5 and 1.0 mg·L\(^{-1}\) were used to calculate \(t_{\text{free}}/\text{MIC}\).

**Safety and tolerability**

Reported AEs in medical charts were used to evaluate the safety of ertapenem. Specific attention was paid to AEs mentioned in earlier studies, i.e. diarrhoea and vomiting. The Naranjo algorithm was used to evaluate for causality between AEs that occurred and ertapenem [19].

**Statistics and pharmacokinetic evaluation**

SPSS 20 was used as statistical software (SPSS, Virginia, IL, USA). Correlations between pharmacokinetic parameters and patient characteristics were analysed using the Spearman correlation coefficient. MIC data were statistically analysed using a methodology for censored MIC data [20].

**Results**

**Patients**

18 patients treated with ertapenem, mean (range) age 29 (13–66) years, were retrieved. Ertapenem was part of the treatment regimen because of suspected extensive drug resistance, intolerance to second-line drugs or a combination of both. Based on the results of the drug susceptibility test, ertapenem was discontinued in three patients who appeared to have drug-susceptible TB. There was an unequal sex distribution as eight (44.4%) patients were male and 10 (55.5%) patients were female. The mean (range) body mass index was 21.3 (13.7–32.6) kg·m\(^{-2}\). Patients originated predominantly from Africa (11 out of 18) and Europe (five out of 18). Patients were primarily diagnosed with pulmonary TB (13 out of 18); extrapulmonary sites were involved in seven patients.

The prescribed dosage of ertapenem was 1000 mg once daily in all patients. The mean (range) total treatment duration of ertapenem was 77 (5–210) days. Drug resistance patterns of the patients to anti-TB agents are shown in Table 1. The most prescribed anti-TB drugs in the 18 patients were: moxifloxacin (17 patients), injectable (16 patients), linezolid (15 patients), clofazimine (eight patients), clarithromycin (six patients) and pyrazinamide (five patients).

In total, 15 patients completed treatment and were cured. Three patients were lost to follow-up. All patients with positive sputum smear converted within a mean (range) period of 17 (0–97) days. Cultures remained negative after culture conversion and no relapse of MDR-TB was observed.

### TABLE 1 Drug resistance patterns of the 18 study patients

<table>
<thead>
<tr>
<th>Drugs by group#</th>
<th>Resistant</th>
<th>Sensitive</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Group 1: first-line oral drugs</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Isoniazid</td>
<td>17 (94.4)</td>
<td>1 (5.55)</td>
</tr>
<tr>
<td>Rifampicin</td>
<td>15 (83.3)</td>
<td>3 (16.6)</td>
</tr>
<tr>
<td>Pyrazinamide</td>
<td>8 (44.4)</td>
<td>8 (44.4)</td>
</tr>
<tr>
<td>Ethambutol</td>
<td>11 (61.1)</td>
<td>6 (33.3)</td>
</tr>
<tr>
<td>Rifabutin</td>
<td>13 (72.2)</td>
<td>4 (22.2)</td>
</tr>
<tr>
<td><strong>Group 2: injectable agents</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Streptomycin</td>
<td>14 (77.7)</td>
<td>4 (22.2)</td>
</tr>
<tr>
<td>Amikacin</td>
<td>3 (16.6)</td>
<td>14 (77.7)</td>
</tr>
<tr>
<td>Kanamycin</td>
<td>3 (16.6)</td>
<td>14 (77.7)</td>
</tr>
<tr>
<td>Capreomycin</td>
<td>5 (27.7)</td>
<td>12 (66.6)</td>
</tr>
<tr>
<td><strong>Group 3: fluoroquinolones</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Moxifloxacin</td>
<td>2 (11.1)</td>
<td>15 (83.3)</td>
</tr>
<tr>
<td><strong>Group 4: oral bacteriostatic second-line agents</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Protionamide</td>
<td>7 (38.8)</td>
<td>10 (55.5)</td>
</tr>
<tr>
<td><strong>Group 5: agents with unclear role in treatment of drug-resistant TB</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Linezolid</td>
<td>17 (94.4)</td>
<td></td>
</tr>
<tr>
<td>Clarithromycin</td>
<td>3 (16.6)</td>
<td>7 (38.8)</td>
</tr>
<tr>
<td>Clofamizine</td>
<td></td>
<td>8 (44.4)</td>
</tr>
<tr>
<td><strong>Other</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ertapenem</td>
<td>18 (100)</td>
<td></td>
</tr>
</tbody>
</table>

Data are presented as n (%). TB: tuberculosis. #: groups defined by the World Health Organization.
Drug susceptibility of *M. tuberculosis* to ertapenem

All the *M. tuberculosis* strains appeared susceptible to ertapenem. However, actual determination of the MIC was complicated by the fact that ertapenem itself appeared an unstable compound at 37°C [17]. This was confirmed by the fact that after 7 days MIC values were lower than after 14 days. In addition, freshly prepared plates showed lower MIC values compared with plates stored at 4°C. The refrigerator-stored plates showed lower MIC values than plates stored at room temperature. If ertapenem was combined with clavulanic acid, all MIC values were even lower.

Pharmacokinetics and pharmacodynamics

The plasma concentration–time curves were obtained in 12 patients with MDR-TB. In the remaining six patients, routine plasma concentrations were collected at a time-point at which they did not yet receive ertapenem or this drug was no longer administered. Three patients had multiple plasma concentration–time curves and these were consistent. The mean curve is shown in figure 1. The mean (range) area under the concentration–time curve up to 24 h (AUC$_{0-24}$) was 544.9 (309–1130) h·mg·L$^{-1}$. The steady state pharmacokinetic parameters are shown in table 2. Based on a MIC of 0.25 mg·L$^{-1}$, 11 out of 12 patients exceeded a minimum of 40% $t_{\text{free}}$>MIC. In nine patients the MDR-TB remained susceptible with a MIC of 0.5 mg·L$^{-1}$. Only two patients exceeded a minimum of 40% $t_{\text{free}}$>MIC with a MIC of 1 mg·L$^{-1}$. The pharmacokinetic population model (KinPOP) of ertapenem showed a mean (range) clearance of 2.26 (0.86–3.19) L·h$^{-1}$ per 1.73 m$^2$ and a mean (range) volume of distribution of 8.79 (4.76–13.57) L.

Safety and tolerability

In general, ertapenem was tolerated very well. In three patients, treatment with ertapenem was stopped. One of these patients suffered from Crohn’s disease and developed MDR-TB after multiple dosages of infliximab, a tumour necrosis factor-α blocker [21, 22]. This patient experienced allergic fever, shortly after administration of ertapenem and ethambutol. After reintroduction this happened again (Naranjo score=4). Both AEs subsided after withdrawal of the offending drug. In the second patient, ertapenem was stopped after an increase in liver enzymes (aspartate aminotransferase: 109 U·L$^{-1}$; alanine aminotransferase: 255 U·L$^{-1}$) after 13 days of treatment with ertapenem. However, after 2 months, while this patient was still on treatment without ertapenem, liver enzymes remained elevated (Naranjo score=1). In the third patient, kanamycin, linezolid and ertapenem were stopped due to line sepsis. This was considered not to be related to ertapenem. After removal of the venous access port, the patient recovered. Ertapenem and a new venous access port were not reintroduced, since they were not indicated anymore, due to low bacillary load at that time, and these i.v. drugs could be substituted with oral antimycobacterial drugs. None of the patients experienced diarrhoea, vomiting or dizziness.

<table>
<thead>
<tr>
<th>Table 2 Pharmacokinetic parameters of ertapenem</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Patient group</strong></td>
</tr>
<tr>
<td>1 g i.v. in MDR-TB patients</td>
</tr>
<tr>
<td>1 g i.v. in healthy volunteers [18]</td>
</tr>
</tbody>
</table>

Data are presented as mean (range) and were calculated using KinFIT. AUC$_{0-24}$: area under the concentration–time curve up to 24 h; C$_{\text{max}}$: maximum observed plasma concentration; MDR-TB: multidrug-resistant tuberculosis.
Discussion

This is the first study, following a clinical report of ertapenem [6], presenting pharmacokinetic and safety data in patients with MDR-TB. In comparison with healthy volunteers [18], MDR-TB patients showed lower AUCo-24 values. The mean volume of distribution calculated by KinFIT was lower for MDR-TB patients than for the healthy volunteers, whereas the mean clearance was higher for the MDR-TB patients than for the healthy volunteers. Our observations are consistent with other studies that showed a lower drug exposure of ertapenem in patients with infectious diseases [23–25]. More surprising was the intervariability in AUC between patients with MDR-TB. Other antimycobacterial drugs also show high variability and lower drug exposure in TB patients [2, 26, 27]. It is not yet completely clear why drug exposure is lower in TB patients. Apparently, stage of disease and altered body composition may potentially help to explain this observation.

Since ertapenem belongs to the class of β-lactams, ertapenem has a time-dependent bactericidal activity. The $t_{\text{free}>\text{MIC}}$ is therefore important to evaluate the efficacy of ertapenem against M. tuberculosis. Nicolau [11] indicated that, in the case of meropenem, with 40% $t_{\text{free}>\text{MIC}}$, bactericidal activity is observed, whereas 20% $t_{\text{free}>\text{MIC}}$ appeared to have bacteriostatic activity. Other studies have mentioned this $t_{\text{free}>\text{MIC}}$ as well [12, 14]. Protein binding of ertapenem was assumed to be 5%, since ertapenem shows concentration-dependent plasma protein binding. Healthy volunteers, who average a peak plasma concentration of 150 mg·L$^{-1}$ after the end of infusion of 1 g of ertapenem, have a percentage of 8% unbound protein. When total drug plasma concentration declines below 50 mg·L$^{-1}$ peak plasma concentration, the percentage of unbound ertapenem is ~5% [18]. It is very promising to notice that the non-species-related breakpoint of ertapenem of 0.5 mg·L$^{-1}$ was exceeded for >40% of the day in the majority of patients, assuming that patients have a protein binding of 5%. At a higher MIC value of 1 mg·L$^{-1}$, bacteriostatic activity could be expected. Therefore, ertapenem seems a very attractive drug for MDR-TB treatment. It seems warranted that doses of ertapenem higher than 1 g·day$^{-1}$ should be used in the treatment of MDR-TB. However, in vitro experiments evaluating pharmacokinetic/pharmacodynamic targets for ertapenem against M. tuberculosis have yet to be performed. The hollow fibre infection model is suitable for pharmacokinetic/pharmacodynamic experiments and has already been used successfully [28].

Besides pharmacokinetics of ertapenem in patients with MDR-TB, additional safety data are described for the first time as well. Only one patient, with Crohn’s disease, experienced AEs that might be potentially related to ertapenem. One can speculate that this may be related to an infusion-related AE, due to a developed immune character, the limited sample size and the absence of a control group, which prevent a meaningful conclusion to correct for degradation [31]. However, these systems are expensive and difficult to manage, so it is not likely that routine drug susceptibility testing will be performed using hollow fibre systems. Another alternative may be the use of E-tests [32]. These are much cheaper and easier to employ, but it is unclear if they can help to overcome the instability of ertapenem. The most important limitations of our study are the retrospective character, the limited sample size and the absence of a control group, which prevent a meaningful conclusion on the efficacy of ertapenem. A further limitation is the inability to define MIC for ertapenem in clinical isolates. Nevertheless, all patients were cured and no relapse was noticed after being treated with the combination regimen including ertapenem. It is probable that the combination of drugs contributed to sputum culture conversion and favourable treatment outcome. This is in line with recently published data on tolerability and outcomes in five patients receiving ertapenem [6].

A recent editorial has proposed a new classification of anti-TB drugs. It marked the potential of carbapenems as group 5 drugs; however, carbapenems are still in need of proper evaluation and clinical evidence [33]. Before ertapenem can be labelled as a group 5 drug and used as part of MDR-TB treatment, a valid procedure to test drug susceptibility has to be made available. Ideally, the use of ertapenem would be supported by the results of a clinical trial.

In conclusion, this study provides new knowledge on the use of ertapenem in patients with MDR-TB, presenting pharmacokinetic and additional safety data.
References


